...to Selective Estrogen Receptor Degrader (SERD) company Seragon Pharmaceuticals Inc....

...ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) and helped found cancer company Aragon Pharmaceuticals Inc. and its spinout Seragon Pharmaceuticals Inc....

...Founded by Charles Sawyers and Richard Heyman, the duo behind Aragon Pharmaceuticals and its spinout Seragon...

...front and up to $350 million in milestones; and Roche (SIX:ROG; OTCQX:RHHBY) bought Aragon’s spinout, Seragon Pharmaceuticals Inc....

...more than $175 million, was founded by the duo behind Aragon Pharmaceuticals and its spinout Seragon...
...Heyman is ORIC's chairman. Together, they previously founded drug-resistant cancer companies Aragon Pharmaceuticals Inc. and Seragon Pharmaceuticals Inc....
...NT5E) - Ecto-5’-nucleotidase; GCCR - Glucocorticoid receptor Elizabeth S. Eaton, Staff Writer ORIC-101 Aragon Pharmaceuticals Inc. Ignyta Inc. ORIC Pharmaceuticals Inc. Seragon Pharmaceuticals Inc....

...flow. Only one of those was an acquisition of a company, the 2014 deal for Seragon Pharmaceuticals Inc....

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....

...Mulroy was president and CEO at Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), and Roychowdhury was CMO of Seragon Pharmaceuticals Inc....
...date. Partner Therapeutics Inc., Boston, Mass. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Cancer Jennie Walters Partner Therapeutics Inc.SanofiRocheSeragonMerrimack...

...its Genentech Inc. unit acquired Seragon Pharmaceuticals Inc. in 2014. This is the second SERD candidate from Seragon...
...see BioCentury Extra, March 29, 2017 & BioCentury Extra, Jan. 12, 2018) . Elizabeth S. Eaton ocrelizumab Ocrevus RG6046 RG6047 Genentech Inc. Seragon Pharmaceuticals Inc. Roche...

...was co-founder, CEO and president of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK). CMO Roychowdhury was CMO of Seragon Pharmaceuticals Inc....